Business Description
Terumo Corp
Share Class Description:
FRA:TUO0: ADRCompare
Compare
Traded in other countries / regions
4543.JapanTRUMY.USA4543.MexicoTUO0.Germany IPO Date
2024-04-03Description
Terumo Corp manufactures and sells medical products and equipment. The firm has three main businesses: blood management, cardiac and vascular, and general hospital. The cardiac and vascular business generates the largest proportion of revenue and sells cardiac and endovascular interventional therapies, cardiovascular surgical systems, neurovascular products, and vascular graft products. The general hospital business includes diabetes management, consumer healthcare, drug and device technologies, and general hospital products. The blood management business sells blood component, therapeutic apheresis, and cellular technologies. Terumo generates the majority of its revenue in Asia, with Japan contributing the largest proportion of Asian revenue.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.8 | |||||
| Equity-to-Asset | 0.72 | |||||
| Debt-to-Equity | 0.19 | |||||
| Debt-to-EBITDA | 1.1 | |||||
| Interest Coverage | 45.48 | |||||
| Piotroski F-Score | 8/9 | |||||
| Altman Z-Score | 6.69 | |||||
| Beneish M-Score | -2.44 | |||||
| WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 9.6 | |||||
| 3-Year EBITDA Growth Rate | 5.3 | |||||
| 3-Year EPS without NRI Growth Rate | 1.8 | |||||
| 3-Year FCF Growth Rate | 10.4 | |||||
| 3-Year Book Growth Rate | 14.1 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 15.2 | |||||
| Future 3-5Y Total Revenue Growth Rate | 8.3 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 31.6 | |||||
| 9-Day RSI | 22.27 | |||||
| 14-Day RSI | 16.29 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.9 | |||||
| Quick Ratio | 1.13 | |||||
| Cash Ratio | 0.52 | |||||
| Days Inventory | 222.01 | |||||
| Days Sales Outstanding | 66.6 | |||||
| Days Payable | 74.58 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Dividend Growth Rate | 12.6 | |||||
| 3-Year Average Share Buyback Ratio | 0.3 | |||||
| Shareholder Yield % | 1.44 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 51.27 | |||||
| Operating Margin % | 14.61 | |||||
| Net Margin % | 11.19 | |||||
| FCF Margin % | 6.87 | |||||
| ROE % | 8.44 | |||||
| ROA % | 6 | |||||
| ROIC % | 7.27 | |||||
| ROC (Joel Greenblatt) % | 20.86 | |||||
| ROCE % | 9.76 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 39.49 | |||||
| PE Ratio without NRI | 39.49 | |||||
| Shiller PE Ratio | 51.25 | |||||
| Price-to-Owner-Earnings | 50.44 | |||||
| PEG Ratio | 8.78 | |||||
| PS Ratio | 4.42 | |||||
| PB Ratio | 3.21 | |||||
| Price-to-Tangible-Book | 5.94 | |||||
| Price-to-Free-Cash-Flow | 64.68 | |||||
| Price-to-Operating-Cash-Flow | 29.23 | |||||
| EV-to-EBIT | 29.75 | |||||
| EV-to-EBITDA | 19.1 | |||||
| EV-to-Revenue | 4.46 | |||||
| EV-to-FCF | 65.22 | |||||
| Price-to-Projected-FCF | 2.75 | |||||
| Price-to-DCF (Earnings Based) | 1.58 | |||||
| Price-to-DCF (FCF Based) | 3.43 | |||||
| Price-to-Median-PS-Value | 1.14 | |||||
| Price-to-Peter-Lynch-Fair-Value | 5.26 | |||||
| Price-to-Graham-Number | 3.23 | |||||
| Price-to-Net-Current-Asset-Value | 20.27 | |||||
| Earnings Yield (Greenblatt) % | 3.36 | |||||
| FCF Yield % | 1.55 | |||||
| Forward Rate of Return (Yacktman) % | 8.51 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Terumo Corp Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 5,790.094 | ||
| EPS (TTM) (€) | 0.434 | ||
| Beta | 0 | ||
| Volatility % | 0 | ||
| 14-Day RSI | 16.29 | ||
| 14-Day ATR (€) | 0.810068 | ||
| 20-Day SMA (€) | 17.745 | ||
| 12-1 Month Momentum % | 0 | ||
| 52-Week Range (€) | 15 - 32.2 | ||
| Shares Outstanding (Mil) | 1,484.77 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 8 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Terumo Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Terumo Corp Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Terumo Corp Frequently Asked Questions
What is Terumo Corp(FRA:TUO0)'s stock price today?
The current price of FRA:TUO0 is €15.20. The 52 week high of FRA:TUO0 is €32.20 and 52 week low is €15.00.
When is next earnings date of Terumo Corp(FRA:TUO0)?
The next earnings date of Terumo Corp(FRA:TUO0) is .
Does Terumo Corp(FRA:TUO0) pay dividends? If so, how much?
Terumo Corp(FRA:TUO0) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers